How quickly does Wegovy work? Weight loss speed, stages and what to realistically expect

Step 1, The first four weeks: appetite shifts before the scales do

The opening pen contains 0.25mg semaglutide. That dose is not intended to produce rapid weight loss; its job is to let your body adjust to the medicine with as little nausea and digestive disruption as possible. Most people at this stage notice that they feel full sooner, that food is on their mind less, or that they are leaving meals unfinished, but the scales may barely move. This is normal and expected.

GI side effects (nausea, loose stools, mild reflux) are most common in this first month and usually settle within a week or two of each dose step. Staying well hydrated and eating smaller, lower-fat meals helps. Your prescriber will have discussed what to watch for; the NHS semaglutide medicines page covers the full side-effect profile in plain language.

Practically speaking, what arrives at this point is a plain, unbranded box via DPD with a tracking link sent to your phone, a pre-filled pen that clicks and locks after each use. The first pen contains four weekly doses.

Step 2, Months two to four: dose increases and the first visible changes

Titration continues roughly every four weeks: 0.25mg to 0.5mg, then to 1.0mg, then to 1.7mg. As the dose rises, appetite suppression deepens and calorie intake tends to fall more consistently. This is the phase where most patients see the first clear movement on the scales.

Research from the STEP programme gives a useful benchmark. By around week 20 (roughly month five), participants on semaglutide had typically lost somewhere between 8% and 10% of their starting body weight. That is an average across a large group, some lose more quickly, some more slowly. The pace is rarely linear; there are weeks where nothing seems to change, followed by a stretch where several pounds shift.

One question our prescribers hear regularly at this stage is whether the medicine has stopped working. Short plateaus during titration are common and are not evidence of treatment failure. Sticking with the prescribed schedule (and with the dietary and activity changes that sit alongside it) matters here. For a fuller look at how the medicine acts on appetite and energy balance, our page on Wegovy and metabolism covers the biological picture in detail.

Step 3, Month five onward: maintenance dose and sustained loss

The 2.4mg maintenance dose is reached at around the five-month mark for most patients. This is when the trial data was generated: in STEP 1 (68 weeks, adults with obesity or overweight plus a weight-related condition), the average weight reduction was around 15% at 2.4mg, published in the New England Journal of Medicine. Roughly one in three participants lost over 20% of their starting weight.

Weight loss at this stage is typically slower on a week-by-week basis but compounds over time. The body does not respond identically to the same dose indefinitely; metabolism adjusts, appetite hormones shift, and progress naturally decelerates. This is not the medicine losing efficacy, it is physiology. Continuing the treatment, sustaining dietary changes and incorporating regular activity all support ongoing results.

NICE's recommendation for semaglutide (TA875) notes that if less than 5% of body weight has been lost after six months at the maintenance dose, continuing treatment should be reviewed. That clinical checkpoint exists to ensure the medicine is genuinely helping each individual, not as an arbitrary rule. Details of the NICE criteria and how private prescribing relates to them are covered on the Wegovy weight loss overview page.

What influences the speed most?

Three things shift the timeline more than anything else. First, how quickly you tolerate dose increases: people who need slower titration because of nausea reach the full dose later, and their meaningful weight-loss phase simply starts later as a result. Second, what happens alongside the medicine: semaglutide suppresses appetite, but dietary quality and movement still determine how efficiently that calorie deficit translates into fat loss. Third, starting weight, someone with a higher BMI typically loses more in absolute terms and may see faster early movement, while someone closer to the eligibility threshold might progress more gradually.

Genetics, previous dieting history, sleep, stress and other medicines can all play a role. It is worth reading about the broader semaglutide and weight loss evidence if you want to understand the range of outcomes across different populations. For questions about whether Wegovy would be appropriate for your specific situation, a free consultation with our prescribers is the right starting point, they review every case the same day it comes in.

Cost is a practical consideration too, especially if you are weighing how long to commit to treatment. Our Wegovy price comparison page sets out what is typically included in private prescription fees, so you can assess the full picture. And if you are still deciding between treatment options, the weight loss overview covers all the licensed medicines available through nume.